Children younger than 6 generally lack fully developed gag reflex and could not swallow solid dosage forms. In addition, one in every 25 adults in US has swallowing problems. Syrup is often gooey, hard to measure and prone to spill. Making it difficult to accurately dose and treat the patient, which leads to ineffective treatment, medication waste, and significant patient compliance issue.

SGC provides a perfect solution for these problems. Building upon its proprietary API-Complexing technology and sugar-free GUMMY ZERO® matrix protected by a large and robust IP portfolio, the company has developed stable and great tasting gummy drugs treating varieties of diseases. With the initial focus on pediatric and geriatric markets, SGC’s current drug development program features a suite of gummy drugs for treating allergy, pain, fever, cough, nausea, insomnia, inflammatory, cardiovascular conditions, and bacterial infection. The company has a diverse gummy drug pipeline in the regulatory approval process and has received the FDA approval for its IND of the very first gummy drug formulation in the world.